Question
stringlengths 31
235
| Answer
stringlengths 1
1k
| Evidence Text
sequencelengths 1
4
| Company Name
stringclasses 48
values | Ticker
stringclasses 48
values | Filing year
float64 2.02k
2.02k
| Filing date
stringclasses 44
values | CIK
float64 2.49k
1.75M
| GICS_Sector
stringclasses 16
values | URL_HTML
stringclasses 51
values | q-id
int64 0
2.31k
| in-prod
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|
What was the diluted earnings per share of Amgen Inc for FY 23? | Amgen Inc's diluted earnings per share was $12.49 for FY 23. | [
"The computations for basic and diluted EPS were as follows (in millions, except per-share data):\n Years ended December 31,\n 2023\n 2022\n 2021\n Income (Numerator):\n Net income for basic and diluted EPS\n $\n 6,717 $\n 6,552 $\n 5,893 \n Shares (Denominator):\n Weighted-average shares for basic EPS\n 535 \n Effect of dilutive securities\n 3 \n 538 \n 3 \n 570 \n 3 \n Weighted-average shares for diluted EPS\n 538 \n 541 \n 573 \n Basic EPS\n $\n Diluted EPS\n $\n 12.56 $\n 12.49 $\n 12.18 $\n 12.11 $\n 10.34 \n 10.28 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 70 | 0 |
How much dividends were paid by Amgen Inc. in FY 23? | Amgen Inc. paid dividends amounting $4,556 million in FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n Years ended December 31, 2023, 2022 and 2021\n (In millions)\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 6,717 $ 6,552 $ 5,893 \n Depreciation, amortization and other 4,071 3,417 3,398 \n Stock-based compensation expense 431 401 341 \n Deferred income taxes (1,273) (1,198) (453)\n Acquired in-process research and development — — 1,505 \n Adjustments for equity method investments 11 891 33 \n Loss on divestiture — 567 — \n (Gains) losses on equity securities (1,565) 127 — \n Other items, net 563 (303) (262)\n Changes in operating assets and liabilities, net of acquisitions:\n Trade receivables, net (1,015) (746) (429)\n Inventories 491 (742) (165)\n Other assets (564) 258 (237)\n Accounts payable (402) 154 (69)\n Accrued income taxes, net (1,031) (647) (854)\n Long-term tax liabilities 371 229 204 \n Accrued sales incentives and allowance 935 846 404 \n Other liabilities 731 (85) (48)\n Net cash provided by operating activities 8,471 9,721 9,261 \n Cash flows from investing activities:\n Cash paid for acquisitions, net of cash acquired (26,989) (3,839) (2,529)\n Purchases of marketable securities (1) (2,587) (8,900)\n Proceeds from sales of marketable securities 1,123 98 4,403 \n Proceeds from maturities of marketable securities 550 1,120 8,831 \n Purchases of property, plant and equipment (1,112) (936) (880)\n Other 225 100 (192)\n Net cash (used in) provided by investing activities (26,204) (6,044) 733 \n Cash flows from financing activities:\n Net proceeds from issuance of debt 27,777 6,919 4,945 \n Extinguishment of debt (647) (297) — \n Repayment of debt (1,454) — (4,150)\n Repurchases of common stock — (6,360) (4,975)\n Dividends paid (4,556) (4,196) (4,013)\n Other (72) (103) (78)\n Net cash provided by (used in) financing activities 21,048 (4,037) (8,271)\n Increase (decrease) in cash and cash equivalents 3,315 (360) 1,723 \n Cash and cash equivalents at beginning of year 7,629 7,989 6,266 \n Cash and cash equivalents at end of year $ 10,944 $ 7,629 $ 7,989"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 71 | 0 |
Which operating expense increased most for Amgen Inc. in FY 23? | Cost of sales increased most by 32% for Amgen Inc. in FY 23. | [
"Operating expenses\n Operating expenses were as follows (dollar amounts in millions):\n Year ended December\n 31, 2023 Change\n Year ended December\n 31, 2022 Change\n Year ended December\n 31, 2021\n Cost of sales $ 8,451 32 % $ 6,406 (1)% $ 6,454 \n % of product sales 31.4 % 25.8 % 26.6 %\n % of total revenues 30.0 % 24.3 % 24.8 %\n Research and development $ 4,784 8 % $ 4,434 (8)% $ 4,819 \n % of product sales 17.8 % 17.9 % 19.8 %\n % of total revenues 17.0 % 16.8 % 18.5 %\n Acquired in-process research and development $ — NM $ — (100)% $ 1,505 \n % of product sales — % — % 6.2 %\n % of total revenues — % — % 5.8 %\n Selling, general and administrative $ 6,179 14 % $ 5,414 1 % $ 5,368 \n % of product sales 23.0 % 21.8 % 22.1 %\n % of total revenues 21.9 % 20.6 % 20.7 %\n Other $ 879 75 % $ 503 * $ 194 \n Total operating expenses $ 20,293 21 % $ 16,757 (9)% $ 18,340 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 72 | 0 |
What was the percentage change in Amgen Inc.'s total operating expenses in FY 22? | Amgen Inc.'s total operating expenses decreased by 9% in FY 22. | [
"Operating expenses\n Operating expenses were as follows (dollar amounts in millions):\n Year ended December\n 31, 2023 Change\n Year ended December\n 31, 2022 Change\n Year ended December\n 31, 2021\n Cost of sales $ 8,451 32 % $ 6,406 (1)% $ 6,454 \n % of product sales 31.4 % 25.8 % 26.6 %\n % of total revenues 30.0 % 24.3 % 24.8 %\n Research and development $ 4,784 8 % $ 4,434 (8)% $ 4,819 \n % of product sales 17.8 % 17.9 % 19.8 %\n % of total revenues 17.0 % 16.8 % 18.5 %\n Acquired in-process research and development $ — NM $ — (100)% $ 1,505 \n % of product sales — % — % 6.2 %\n % of total revenues — % — % 5.8 %\n Selling, general and administrative $ 6,179 14 % $ 5,414 1 % $ 5,368 \n % of product sales 23.0 % 21.8 % 22.1 %\n % of total revenues 21.9 % 20.6 % 20.7 %\n Other $ 879 75 % $ 503 * $ 194 \n Total operating expenses $ 20,293 21 % $ 16,757 (9)% $ 18,340 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 73 | 0 |
How much did Amgen Inc. spend on its R&D in FY 23? | Amgen spent over $4.784 million in its R&D activities in FY 23. | [
"Operating expenses\n Operating expenses were as follows (dollar amounts in millions):\n Year ended December\n 31, 2023 Change\n Year ended December\n 31, 2022 Change\n Year ended December\n 31, 2021\n Cost of sales $ 8,451 32 % $ 6,406 (1)% $ 6,454 \n % of product sales 31.4 % 25.8 % 26.6 %\n % of total revenues 30.0 % 24.3 % 24.8 %\n Research and development $ 4,784 8 % $ 4,434 (8)% $ 4,819 \n % of product sales 17.8 % 17.9 % 19.8 %\n % of total revenues 17.0 % 16.8 % 18.5 %\n Acquired in-process research and development $ — NM $ — (100)% $ 1,505 \n % of product sales — % — % 6.2 %\n % of total revenues — % — % 5.8 %\n Selling, general and administrative $ 6,179 14 % $ 5,414 1 % $ 5,368 \n % of product sales 23.0 % 21.8 % 22.1 %\n % of total revenues 21.9 % 20.6 % 20.7 %\n Other $ 879 75 % $ 503 * $ 194 \n Total operating expenses $ 20,293 21 % $ 16,757 (9)% $ 18,340 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 74 | 0 |
Was there any year-on-year change in Amgen Inc.'s selling, general and administrative expenses in FY 23? | Amgen Inc.'s selling, general and administrative expenses increased by 14% in FY 23. | [
"Operating expenses\n Operating expenses were as follows (dollar amounts in millions):\n Year ended December\n 31, 2023 Change\n Year ended December\n 31, 2022 Change\n Year ended December\n 31, 2021\n Cost of sales $ 8,451 32 % $ 6,406 (1)% $ 6,454 \n % of product sales 31.4 % 25.8 % 26.6 %\n % of total revenues 30.0 % 24.3 % 24.8 %\n Research and development $ 4,784 8 % $ 4,434 (8)% $ 4,819 \n % of product sales 17.8 % 17.9 % 19.8 %\n % of total revenues 17.0 % 16.8 % 18.5 %\n Acquired in-process research and development $ — NM $ — (100)% $ 1,505 \n % of product sales — % — % 6.2 %\n % of total revenues — % — % 5.8 %\n Selling, general and administrative $ 6,179 14 % $ 5,414 1 % $ 5,368 \n % of product sales 23.0 % 21.8 % 22.1 %\n % of total revenues 21.9 % 20.6 % 20.7 %\n Other $ 879 75 % $ 503 * $ 194 \n Total operating expenses $ 20,293 21 % $ 16,757 (9)% $ 18,340 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 75 | 0 |
What was Amgen Inc.'s cost of sales ratio for FY 23? | Amgen's cost-of-sales ratio was 29.9% for FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 76 | 0 |
What was Amgen Inc.'s return on assets for FY 23? | Amgen Inc.'s return on assets was 0.069 or 6.9% for FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573",
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 77 | 0 |
What is Amgen Inc.'s return on equity for FY 23? | Amgen Inc.'s return on equity is 1.07 or 107% for FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573",
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 78 | 0 |
What was Amgen Inc.'s asset turnover ratio for FY 23? | Amgen Inc.'s asset turnover ratio for FY 23 was 29.1%. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573",
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 79 | 0 |
What was Amgen Inc.'s debt-to-asset ratio for FY 23? | Amgen Inc.'s debt-to-asset ratio was 93.58% for FY 23. | [
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 80 | 0 |
What was Amgen Inc.'s current ratio for FY 23? | Amgen Inc's current ratio was 1.65 for FY 23. | [
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 81 | 0 |
What was Amgen Inc.'s interest coverage ratio for FY 23? | Amgen Inc.'s interest coverage ratio was 2.75 for FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 82 | 0 |
What was Amgen Inc.'s total stock-based compensation expense for FY 23? | Amgen Inc.'s total stock-based compensation expense was $431 million for FY 23. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF CASH FLOWS\n Years ended December 31, 2023, 2022 and 2021\n (In millions)\n 2023 2022 2021\n Cash flows from operating activities:\n Net income $ 6,717 $ 6,552 $ 5,893 \n Depreciation, amortization and other 4,071 3,417 3,398 \n Stock-based compensation expense 431 401 341 \n Deferred income taxes (1,273) (1,198) (453)\n Acquired in-process research and development — — 1,505 \n Adjustments for equity method investments 11 891 33 \n Loss on divestiture — 567 — \n (Gains) losses on equity securities (1,565) 127 — \n Other items, net 563 (303) (262)\n Changes in operating assets and liabilities, net of acquisitions:\n Trade receivables, net (1,015) (746) (429)\n Inventories 491 (742) (165)\n Other assets (564) 258 (237)\n Accounts payable (402) 154 (69)\n Accrued income taxes, net (1,031) (647) (854)\n Long-term tax liabilities 371 229 204 \n Accrued sales incentives and allowance 935 846 404 \n Other liabilities 731 (85) (48)\n Net cash provided by operating activities 8,471 9,721 9,261 \n Cash flows from investing activities:\n Cash paid for acquisitions, net of cash acquired (26,989) (3,839) (2,529)\n Purchases of marketable securities (1) (2,587) (8,900)\n Proceeds from sales of marketable securities 1,123 98 4,403 \n Proceeds from maturities of marketable securities 550 1,120 8,831 \n Purchases of property, plant and equipment (1,112) (936) (880)\n Other 225 100 (192)\n Net cash (used in) provided by investing activities (26,204) (6,044) 733 \n Cash flows from financing activities:\n Net proceeds from issuance of debt 27,777 6,919 4,945 \n Extinguishment of debt (647) (297) — \n Repayment of debt (1,454) — (4,150)\n Repurchases of common stock — (6,360) (4,975)\n Dividends paid (4,556) (4,196) (4,013)\n Other (72) (103) (78)\n Net cash provided by (used in) financing activities 21,048 (4,037) (8,271)\n Increase (decrease) in cash and cash equivalents 3,315 (360) 1,723 \n Cash and cash equivalents at beginning of year 7,629 7,989 6,266 \n Cash and cash equivalents at end of year $ 10,944 $ 7,629 $ 7,989 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 83 | 0 |
What were Amgen Inc.'s net trade receivables for FY 23? | Amgen Inc.'s net trade receivables for FY 23 were $7,268 million. | [
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 84 | 0 |
What was Amgen Inc.'s effective tax rate for FY 23? | Amgen Inc.'s effective tax rate for FY 21 was 14.5%. | [
" Nonoperating expenses/income and income taxes\n Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):\n Years ended December 31,\n 2023\n 2022\n 2021\n Interest expense, net\n $\n Other income (expense), net\n Provision for income taxes\n $\n (2,875)\n 2,833 \n $\n $\n (1,406)\n (814)\n $\n $\n (1,197)\n 259 \n $\n Effective tax rate\n Interest expense, net\n 1,138 \n 14.5 %\n $\n 794 \n 10.8 %\n $\n 808 \n 12.1 %"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 85 | 0 |
Was there any change in the effective tax rate of Amgen Inc. in FY 23 as compared to the previous year? | The effective tax rate for Amgen Inc. increased by 3.7% in FY 21. | [
" Nonoperating expenses/income and income taxes\n Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions):\n Years ended December 31,\n 2023\n 2022\n 2021\n Interest expense, net\n $\n Other income (expense), net\n Provision for income taxes\n $\n (2,875)\n 2,833 \n $\n $\n (1,406)\n (814)\n $\n $\n (1,197)\n 259 \n $\n Effective tax rate\n Interest expense, net\n 1,138 \n 14.5 %\n $\n 794 \n 10.8 %\n $\n 808 \n 12.1 %"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 86 | 0 |
What was the Amgen Inc. provision for income taxes for FY 23? | Amgen Inc. FY 23 provision for income taxes was $1,138 million. | [
"AMGEN INC.\n CONSOLIDATED STATEMENTS OF INCOME\n Years ended December 31, 2023, 2022 and 2021\n (In millions, except per-share data)\n 2023 2022 2021\n Revenues:\n Product sales $ 26,910 $ 24,801 $ 24,297 \n Other revenues 1,280 1,522 1,682 \n Total revenues 28,190 26,323 25,979 \n Operating expenses:\n Cost of sales 8,451 6,406 6,454 \n Research and development 4,784 4,434 4,819 \n Acquired in-process research and development — — 1,505 \n Selling, general and administrative 6,179 5,414 5,368 \n Other 879 503 194 \n Total operating expenses 20,293 16,757 18,340 \n Operating income 7,897 9,566 7,639 \n Other income (expense):\n Interest expense, net (2,875) (1,406) (1,197)\n Other income (expense), net 2,833 (814) 259 \n Income before income taxes 7,855 7,346 6,701 \n Provision for income taxes 1,138 794 808 \n Net income $ 6,717 $ 6,552 $ 5,893 \n Earnings per share:\n Basic $ 12.56 $ 12.18 $ 10.34 \n Diluted $ 12.49 $ 12.11 $ 10.28 \n Shares used in the calculation of earnings per share:\n Basic 535 538 570\n Diluted 538 541 573"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 87 | 0 |
What was the total lease liability for Amgen Inc. for FY 23? | Amgen Inc.'s total lease liability for FY 23 was $810 million. | [
" The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in\n millions):\n December 31,\n Consolidated Balance Sheets locations\n 2023\n 2022\n Assets:\n Other noncurrent assets\n $\n 651 $\n 579 \n Liabilities:\n Accrued liabilities\n Other noncurrent liabilities\n $\n 119 $\n 156 \n 691 \n 539 \n Total lease liabilities\n $\n 810 $ 695"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 88 | 0 |
What was Amgen Inc.'s total net lease cost for FY 23? | Amgen Inc.'s total net lease cost for FY 23 was $180 million. | [
"The components of net lease costs were as follows (in millions):\n Years ended December 31,\n Lease costs\n 2023\n 2022\n 2021\n Operating\n (1)\n Sublease income\n Total net lease costs\n $\n 208 $\n (28)\n 218 $\n (32)\n 237 \n (38)\n $\n ____________\n (1) \n 180 $\n Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2023, 2022 and 2021.\n F-35\n 186 $\n 199"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 89 | 0 |
How much of Amgen Inc.'s lease liabilities will be maturing in FY 24? | Amgen's lease liabilities of $138 million will be maturing in FY 24. | [
"Maturities of lease liabilities as of December 31, 2023, were as follows (in millions):\n Maturity dates\n Amounts\n 2024\n $\n 2025\n 2026\n 138 \n 121 \n 109 \n 2027\n 2028\n 95 \n 74 \n Thereafter\n Total lease payments\n (1)\n 440 \n 977 \n Less imputed interest\n Present value of lease liabilities\n (167)\n $\n ____________\n (1) \n 810 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 90 | 0 |
What was Amgen Inc.'s sublease income for FY 23? | Amgen Inc.'s sublease income for FY 23 was -$28 million. | [
"The components of net lease costs were as follows (in millions):\n Years ended December 31,\n Lease costs\n 2023\n 2022\n 2021\n Operating\n (1)\n Sublease income\n Total net lease costs\n $\n 208 $\n (28)\n 218 $\n (32)\n 237 \n (38)\n $\n ____________\n (1) \n 180 $\n Includes short-term leases and variable lease costs, which were not material for the years ended December 31, 2023, 2022 and 2021.\n F-35\n 186 $\n 199"
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 91 | 0 |
What were Amgen Inc. accounts payable as of December 31, 2023? | Amgen Inc. accounts payable amounted to $1,590 million as of December 31, 2023. | [
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 92 | 0 |
What was Amgen Inc.'s current portion of long-term debt as of December 31, 2023? | Amgen Inc.'s current portion of long-term debt was $1,443 million as of December 31, 2023. | [
"AMGEN INC.\n CONSOLIDATED BALANCE SHEETS\n December 31, 2023 and 2022\n (In millions, except per-share data)\n 2023\n 2022\n ASSETS\n Current assets:\n Cash and cash equivalents\n Marketable securities\n Trade receivables, net\n $\n 10,944 $\n — \n 7,629 \n 1,676 \n 7,268 \n Inventories\n Other current assets\n 9,518 \n 5,563 \n 4,930 \n 2,602 \n 2,388 \n Total current assets\n 30,332 \n 22,186 \n Property, plant and equipment, net\n 5,941 \n Intangible assets, net\n 5,427 \n 32,641 \n Goodwill\n Other noncurrent assets\n 18,629 \n 16,080 \n 15,529 \n 9,611 \n 5,899 \n Total assets\n $\n 97,154 $\n 65,121 \n LIABILITIES AND STOCKHOLDERS’ EQUITY\n Current liabilities:\n Accounts payable\n Accrued liabilities\n $\n 1,590 $\n 1,572 \n 15,359 \n Current portion of long-term debt\n 1,443 \n 12,524 \n 1,591 \n Total current liabilities\n 18,392 \n Long-term debt\n 15,687 \n 63,170 \n Long-term deferred tax liabilities\n Long-term tax liabilities\n 2,354 \n 37,354 \n 11 \n 4,680 \n Other noncurrent liabilities\n 2,326 \n 5,757 \n 2,651 \n Contingencies and commitments\n Stockholders’ equity:\n Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;\n outstanding—535.4 shares in 2023 and 534.0 shares in 2022\n Accumulated deficit\n Accumulated other comprehensive loss\n Total stockholders’ equity\n Total liabilities and stockholders’ equity\n See accompanying notes.\n F-7\n 33,070 \n (26,549)\n (289)\n 6,232 \n $\n 97,154 $\n 32,514 \n (28,622)\n (231)\n 3,661 \n 65,121 \n "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 93 | 0 |
What were Amgen Inc.'s net intangible assets for FY 23? | Amgen Inc.'s net intangible assets for FY 23 totaled at $32,641 million. | [
" Other intangible assets\n Other intangible assets consisted of the following (in millions):\n December 31,\n 2023 2022\n \n Gross carrying amounts\n Accumulated amortization\n Other intangible assets, net\n Gross carrying amounts\n Accumulated amortization\n Other intangible assets, net\n Finite-lived intangible assets:\n Developed-product-technology rights $ 48,631 $ (18,049) $ 30,582 $ 29,028 $ (15,045) $ 13,983 \n Licensing rights 3,865 (3,265) 600 3,864 (3,123) 741 \n Marketing-related rights 1,339 (1,264) 75 1,326 (1,167) 159 \n R&D technology rights 1,394 (1,228) 166 1,378 (1,190) 188 \n Total finite-lived intangible assets 55,229 (23,806) 31,423 35,596 (20,525) 15,071 \n Indefinite-lived intangible assets:\n IPR&D 1,218 — 1,218 1,009 — 1,009 \n Total other intangible assets $ 56,447 $ (23,806) $ 32,641 $ 36,605 $ (20,525) $ 16,080 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 94 | 0 |
What was the accumulated amortization cost for Amgen Inc.'s intangible assets for FY 23? | The accumulated amortization cost for Amgen Inc.'s intangible assets for FY 23 was $23,806 million. | [
" Other intangible assets\n Other intangible assets consisted of the following (in millions):\n December 31,\n 2023 2022\n \n Gross carrying amounts\n Accumulated amortization\n Other intangible assets, net\n Gross carrying amounts\n Accumulated amortization\n Other intangible assets, net\n Finite-lived intangible assets:\n Developed-product-technology rights $ 48,631 $ (18,049) $ 30,582 $ 29,028 $ (15,045) $ 13,983 \n Licensing rights 3,865 (3,265) 600 3,864 (3,123) 741 \n Marketing-related rights 1,339 (1,264) 75 1,326 (1,167) 159 \n R&D technology rights 1,394 (1,228) 166 1,378 (1,190) 188 \n Total finite-lived intangible assets 55,229 (23,806) 31,423 35,596 (20,525) 15,071 \n Indefinite-lived intangible assets:\n IPR&D 1,218 — 1,218 1,009 — 1,009 \n Total other intangible assets $ 56,447 $ (23,806) $ 32,641 $ 36,605 $ (20,525) $ 16,080 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 95 | 0 |
What were the total available-for-sale investments for Amgen Inc. as of FY 23? | Amgen Inc.'s total available-for-sale investments were $10,404 million in FY 23. | [
"Available-for-sale investments\n The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale,\n by type of security were as follows (in millions):\n Types of securities as of December 31, 2023\n Amortized \n cost\n Gross \n unrealized \n gains\n Gross \n unrealized \n losses\n Fair \n values\n U.S. Treasury bills\n $\n Money market mutual funds\n Other short-term interest-bearing securities\n — $\n 10,266 \n — $\n — \n — $\n — \n — \n 10,266 \n 138 \n — — 138 \n Total available-for-sale investments\n $ 10,404 $ — $ — $ 10,404 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 96 | 0 |
Which was the major investment security for Amgen Inc. as of December 31, 2023? | As of December 31, 2023, Amgen Inc. had the majority of its investments amounting $2,659 million in money market securities. | [
" Available-for-sale investments\n The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale,\n by type of security were as follows (in millions):\n Types of securities as of December 31, 2023\n Amortized \n cost\n Gross \n unrealized \n gains\n Gross \n unrealized \n losses\n Fair \n values\n U.S. Treasury bills\n $\n Money market mutual funds\n Other short-term interest-bearing securities\n — $\n 10,266 \n — $\n — \n — $\n — \n — \n 10,266 \n 138 \n — — 138 \n Total available-for-sale investments\n $ 10,404 $ — $ — $ 10,404 \n Gross \n Amortized \n Types of securities as of December 31, 2022\n cost\n unrealized \n gains\n Gross \n unrealized \n losses\n Fair \n values\n U.S. Treasury bills\n $\n Money market mutual funds\n 1,676 $\n 2,659 \n — $\n — \n — $\n — \n 1,676 \n 2,659 \n Other short-term interest-bearing securities — — — — \n Total available-for-sale investments $ 4,335 $ — $ — $ 4,335 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 97 | 0 |
What was Amgen Inc.'s total amount of inventories for FY 23? | Amgen Inc.'s total inventories for FY 23 amounted to $9,518 million. | [
" 11. Inventories\n Inventories consisted of the following (in millions):\n Raw materials\n December 31,\n 2023\n 2022\n $\n Work in process\n Finished goods\n 993 $\n 5,747 \n 828 \n 3,098 \n 2,778 \n 1,004 \n Total inventories\n (1)\n $\n 9,518 $ 4,930 "
] | AMGEN INC | AMGN | 2,024 | 2024-02-14 | 318,154 | Healthcare | https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm | 98 | 0 |
What was the total revenue in the fiscal year 2023 for CVS Health Corp? | The revenue for the fiscal year 2023 was $ 357,776 million for CVS Health Corp | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 99 | 0 |
Which revenue line item had the highest revenue in all the three years combined , FY 2021, FY 2022 and FY 2023, for CVS Health Corp? | The revenue line item with the highest revenue in all the three years combined was Products for CVS Health Corp | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 100 | 0 |
What is the percentage of Premiums revenue in terms of total revenue for the fiscal year 2023 for CVS Health Corp? | The percentage of premiums revenue in terms of total revenue for CVS Health Corp was 27.72% | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 101 | 0 |
What was the consolidated total revenue for front store in the fiscal year 2023 for CVS Health Corp? | The consolidated total for the fiscal year 2023 for Front store was $22,458 for CVS Health Corp | [
"Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2023, 2022 and 2021: In millions Health Care Benefits Health Services Pharmacy & Consumer Wellness Corporate/ Other Intersegment Eliminations Consolidated Totals 2023 Major goods/services lines: Pharmacy $ — $ 180,710 $ 92,111 $ — $ (49,369) $ 223,452 Front Store — — 22,458 — — 22,458 Premiums 99,144 — — 48 — 99,192 Net investment income (loss) 765 (1) (5) 394 — 1,153 Other 5,737 6,134 2,199 9 (2,558) 11,521 Total $ 105,646 $ 186,843 $ 116,763 $ 451 $ (51,927) $ 357,776 Health Services distribution channel: Pharmacy network $ 112,718 Mail & specialty 67,992 Net investment income (loss) (1) Other 6,134 Total $ 186,843 2022 Major goods/services lines: Pharmacy $ — $ 166,793 $ 83,480 $ — $ (45,154) $ 205,119 Front Store — — 22,780 — — 22,780 Premiums 85,274 — — 56 — 85,330 Net investment income (loss) 476 — (44) 406 — 838 Other 5,600 2,783 2,380 68 (2,431) 8,400 Total $ 91,350 $ 169,576 $ 108,596 $ 530 $ (47,585) $ 322,467"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 102 | 0 |
How much did the consolidated total revenue grow from fiscal year 2022 to fiscal year 2023 for Pharmacy for CVS Health Corp? | The consolidated total revenue grew from fiscal year 2022 to fiscal year 2023 for Pharmacy for CVS Health Corp by 8.9% | [
"Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2023, 2022 and 2021: In millions Health Care Benefits Health Services Pharmacy & Consumer Wellness Corporate/ Other Intersegment Eliminations Consolidated Totals 2023 Major goods/services lines: Pharmacy $ — $ 180,710 $ 92,111 $ — $ (49,369) $ 223,452 Front Store — — 22,458 — — 22,458 Premiums 99,144 — — 48 — 99,192 Net investment income (loss) 765 (1) (5) 394 — 1,153 Other 5,737 6,134 2,199 9 (2,558) 11,521 Total $ 105,646 $ 186,843 $ 116,763 $ 451 $ (51,927) $ 357,776 Health Services distribution channel: Pharmacy network $ 112,718 Mail & specialty 67,992 Net investment income (loss) (1) Other 6,134 Total $ 186,843 2022 Major goods/services lines: Pharmacy $ — $ 166,793 $ 83,480 $ — $ (45,154) $ 205,119 Front Store — — 22,780 — — 22,780 Premiums 85,274 — — 56 — 85,330 Net investment income (loss) 476 — (44) 406 — 838 Other 5,600 2,783 2,380 68 (2,431) 8,400 Total $ 91,350 $ 169,576 $ 108,596 $ 530 $ (47,585) $ 322,467"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 103 | 0 |
What was the CAGR for Product for CVS Health Corp for the fiscal year 2023 from fiscal year 2021? | The CAGR for total revenues was 6.36% for CVS Health Corp for the fiscal year 2023 from the fiscal year 2021 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 104 | 0 |
Was the CAGR from 2021 to 2023 for Product higher than the Year over year growth in Product from fiscal year 2022 to fiscal year 2023 for CVS Health Corp? | No, the Year over year growth from fiscal year 2022 to fiscal year 2023 was greater than the CAGR from 2021 to 2023 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 105 | 0 |
Which revenue line item had the highest increase year over year from fiscal year 2022 to fiscal year 2023 for CVS Health Corp? | The highest year over year growth was observed in Net Investments income | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 106 | 0 |
What was net investment income in the fiscal year 2022 for CVS Health Corp? | The net investment income in the fiscal year 2022 for CVS Health Corp was $838 million | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 107 | 0 |
Which business segment revenue had the highest revenue in the fiscal year 2023 for CVS Health Corp? | Health services had the highest revenue in the fiscal year 2023 with $186,843 million in total revenues | [
"Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2023, 2022 and 2021: In millions Health Care Benefits Health Services Pharmacy & Consumer Wellness Corporate/ Other Intersegment Eliminations Consolidated Totals 2023 Major goods/services lines: Pharmacy $ — $ 180,710 $ 92,111 $ — $ (49,369) $ 223,452 Front Store — — 22,458 — — 22,458 Premiums 99,144 — — 48 — 99,192 Net investment income (loss) 765 (1) (5) 394 — 1,153 Other 5,737 6,134 2,199 9 (2,558) 11,521 Total $ 105,646 $ 186,843 $ 116,763 $ 451 $ (51,927) $ 357,776 Health Services distribution channel: Pharmacy network $ 112,718 Mail & specialty 67,992 Net investment income (loss) (1) Other 6,134 Total $ 186,843 2022 Major goods/services lines: Pharmacy $ — $ 166,793 $ 83,480 $ — $ (45,154) $ 205,119 Front Store — — 22,780 — — 22,780 Premiums 85,274 — — 56 — 85,330 Net investment income (loss) 476 — (44) 406 — 838 Other 5,600 2,783 2,380 68 (2,431) 8,400 Total $ 91,350 $ 169,576 $ 108,596 $ 530 $ (47,585) $ 322,467"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 108 | 0 |
What was the gross profit margin for fiscal year 2023 for CVS Health Corp? | The gross profit margin for fiscal year 2023 was 39.32% | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 109 | 0 |
Did the gross profit margin increase or decrease between fiscal year 2022 and fiscal year 2023 for CVS Health Corp? | Yes, The gross profit margin increased from 38.94% in fiscal year 2022 to 39.32% in fiscal year 2023. | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 110 | 0 |
What was the Cost of products sold in the fiscal year 2021 for CVS Health Corp? | The cost of products sold in fiscal year 2021 was $175,803 million | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 111 | 0 |
What was the operating income or loss for the fiscal year 2023 for CVS Health Corp? | The operating income or loss for the fiscal year 2023 was $13,743 million | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 112 | 0 |
What was the operating profit margin in fiscal year 2023 for CVS Health Corp? | The operating profit margin in fiscal year 2023 was 3.84% | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 113 | 0 |
Did the operating profit margin improve or worsen between fiscal year 2022 and fiscal year 2023 for CVS Health Corp? | No, the operating profit margin decreased from 2.46% in fiscal year 2022 to 3.84% in fiscal year 2023 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 114 | 0 |
What was the basic net income per share attributable to CVS health Corp for the fiscal year 2023? | The basic net income per share attributable to CVS health Corp for the fiscal year 2023 was $6.49 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 115 | 0 |
What was the diluted net income per share attributable to CVS health Corp for the fiscal year 2023? | The diluted net income per share attributable to CVS health Corp for the fiscal year 2023 was $6.47 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 116 | 0 |
What was the YoY change in basic net income per share attributable to CVS health Corp for the fiscal year 2023 from 2022? | the YoY change in basic net income per share attributable to CVS health Corp for the fiscal year 2023 from 2022 was 97.26% | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 117 | 0 |
What was the dividend declared per share in fiscal year 2023 for CVS Health Corp? | The dividend declared per in fiscal year 2023 for CVS Health Corp was $2.42 per share | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 118 | 0 |
What was the change in the dividend declared per share YoY, from fiscal year 2022 to fiscal year 2023, for CVS Health Corp? | The change in the dividend declared per share YoY, from fiscal year 2022 to fiscal year 2023, for CVS Health Corp was 10% | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 119 | 0 |
What was the total operating costs for the fiscal year 2023 for CVS Health Corp? | The total operating costs for the fiscal year 2023 for CVS Health Corp was $344,033 million | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 120 | 0 |
What was the YoY change in the total operating costs from the fiscal year 2022 to fiscal year 2023 for CVS Health Corp? | The total operating costs increased YoY by 9.39%. | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 121 | 0 |
Which operating cost line item was the highest in fiscal year 2023 apart from Cost of Products sold for CVS Health Corp? | Health Care Costs was the highest after cost of products at $86,247 million | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 122 | 0 |
What was the value of experience-rated products in the company's investment portfolio for the fiscal year 2023 for CVS Health Corp? | The value of experience-rated products in the company's investment portfolio for the fiscal year 2023 for CVS Health Corp was $723 million. | [
"Investments\nThe Company’s investment portfolio supported the following products at December 31, 2023 and 2022:\nIn millions 2023 2022\nExperience-rated products $ 723 $ 744\nRemaining products 25,555 23,147\nTotal investments $ 26,278 $ 23,891"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 123 | 0 |
What was the Quick ratio for the fiscal year 2023 for CVS Health Corp? | The quick ratio for CVS Health Corp for the fiscal year 2023 was 0.63 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 124 | 0 |
Did the Quick ratio change YoY from fiscal year 2022 to fiscal year 2023 for CVS Health Corp? | Yes, The Quick ratio slightly changed YoY from 0.67 in fiscal year 2022 to 0.63 in fiscal year 2023 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 125 | 0 |
What was the current ratio for the fiscal year 2023 for CVS Health Corp? | The current ratio for CVS Health Corp for the fiscal year 2023 was 0.87 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 126 | 0 |
What was the change YoY in percentage terms in the current ratio for fiscal year 2023 for CVS Health Corp? | The YoY change in percentage terms from fiscal year 2022 to fiscal year 2023 for CVS Health Corp was -8.42% | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 127 | 0 |
What was the debt to assets ratio for the fiscal year 2023 for CVS Health Corp? | The debt to assets ratio for CVS Health Corp for the fiscal year 2023 was 0.7 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 128 | 0 |
What was the debt to equity ratio for the fiscal year 2023 for CVS Health Corp? | The debt to equity ratio for CVS Health Corp for the fiscal year 2023 was 2.26 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 129 | 0 |
What was the debt to total capital ratio for the fiscal year 2023 for CVS Health Corp? | The debt to total capital ratio for CVS Health Corp for the fiscal year 2023 was 0.69 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 130 | 0 |
What was the Asset turnover ratio for the fiscal year 2023 for CVS Health Corp? | The Asset turnover ratio for the fiscal year 2023 was 1.5 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275",
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 131 | 0 |
What was the ROE for the fiscal year 2023 for CVS Health Corp? | The ROE for the fiscal year 2023 for CVS Health Corp was 11.24% | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275",
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 132 | 0 |
What was the debt service coverage ratio for the fiscal year 2023 for CVS Health Corp? | The debt service coverage ratio for the fiscal year 2023 for CVS Health Corp was 0.17 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275",
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 133 | 0 |
What was the interest coverage ratio for the fiscal year 2023 for CVS Health Corp? | The interest coverage ratio for the fiscal year 2023 for CVS Health Corp was 5.17 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 134 | 0 |
What was the Capital intensity ratio for the fiscal year 2023 for CVS Health Corp? | The Capital intensity ratio for the fiscal year 2023 for CVS Health Corp was 0.67 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275",
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 135 | 0 |
What was the value of the preferred stock issued by CVS Health Corp for fiscal year 2023? | The value of the preferred stock issued by CVS Health Corp for fiscal year 2023 was $0 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 136 | 0 |
How many common stock shares were authorized for CVS Health Corp for fiscal year 2023? | The common stock shares authorized for CVS Health Corp for fiscal year 2023 was 3,200 shares. | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 137 | 0 |
What was the Long term investments for the fiscal year ending 2023 for CVS Health Corp? | The Long term investments for the fiscal year ending 2023 for CVS Health Corp was $23,019 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 138 | 0 |
What was the YoY % change in the long-term investments for CVS Health Corp from fiscal year 2022 to fiscal year 2023? | The YoY change in the long-term investments for CVS Health Corp from fiscal year 2022 to fiscal year 2023 was an increase of 9.12%. | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 139 | 0 |
What was the total of inventories in fiscal year 2023 for CVS Health Corp? | The total of inventories in fiscal year 2023 for CVS Health Corp was $18,025 million | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 140 | 0 |
What was the YoY % change in inventories for CVS Health Corp the fiscal year 2022 to fiscal year 2023? | The YoY change in inventories for CVS Health Corp from the fiscal year 2022 to fiscal year 2023 was a decrease of 5.58%. | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 141 | 0 |
What were the total intangible assets, net for CVS Health Corp for the fiscal year 2023? | The total intangible assets, net for CVS Health Corp for the fiscal year 2023 was $29,234 | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 142 | 0 |
What was the YoY % change in intangible assets, net for CVS Health Corp from fiscal year 2022 to fiscal year 2023? | The YoY % change in intangible assets, net for CVS Health Corp from fiscal year 2022 to fiscal year 2023 was an increase of 17.86% | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 143 | 0 |
Was there any goodwill impairment expense charged for the fiscal year 2023 for CVS Health Corp? | No, there was no goodwill impairment charged for the fiscal year 2023 | [
"Consolidated Statements of Operations\nFor the Years Ended December 31,\nIn millions, except per share amounts 2023 2022 2021\nRevenues:\nProducts $ 245,138 $ 226,616 $ 203,738\nPremiums 99,192 85,330 76,132\nServices 12,293 9,683 11,042\nNet investment income 1,153 838 1,199\nTotal revenues 357,776 322,467 292,111\nOperating costs:\nCost of products sold 217,098 196,892 175,803\nHealth care costs 86,247 71,073 64,188\nRestructuring charges 507 — —\nOpioid litigation charges — 5,803 —\nLoss on assets held for sale 349 2,533 —\nStore impairments — — 1,358\nGoodwill impairment — — 431\nOperating expenses 39,832 38,212 37,021\nTotal operating costs 344,033 314,513 278,801\nOperating income 13,743 7,954 13,310\nInterest expense 2,658 2,287 2,503\nLoss on early extinguishment of debt — — 452\nOther income (88) (169) (182)\nIncome before income tax provision 11,173 5,836 10,537\nIncome tax provision 2,805 1,509 2,548\nNet income 8,368 4,327 7,989\nNet (income) loss attributable to noncontrolling interests (24) (16) 12\nNet income attributable to CVS Health $ 8,344 $ 4,311 $ 8,001\nNet income per share attributable to CVS Health:\nBasic $ 6.49 $ 3.29 $ 6.07\nDiluted 6.47 3.26 6.02\nWeighted average shares outstanding:\nBasic $ 1,285 1,312 $ 1,319\nDiluted 1,290 1,323 1,329\nDividends declared per share $ 2.42 $ 2.20 $ 2.00"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 144 | 0 |
How much was the long-term debt for CVS Health Corp for fiscal year 2023? | The long-term debt for CVS Health Corp for fiscal year 2023 was $58,638 million | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 145 | 0 |
What was the YoY % change in long-term debt for CVS Health Corp for the fiscal year 2023 to fiscal year 2022 ? | The long-term debt for CVS Health Corp showed a YoY change of 16.17% for the fiscal year 2023 from the fiscal year 2022 for CVS Health Corp. | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 146 | 0 |
How much was the Long-term operating lease liabilities for CVS Health Corp for fiscal year 2023? | The Long-term operating lease liabilities for CVS Health Corp for fiscal year 2023 was $16,034 million | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 147 | 0 |
What was the YoY % change in Long-term operating lease liabilities for CVS Health Corp for the fiscal year 2023 from fiscal year 2022? | The Long-term operating lease liabilities for CVS Health Corp for the fiscal year 2023 in comparison to the fiscal year 2022 showed a change of negative 0.45% | [
"Consolidated Balance Sheets\nAt December 31,\nIn millions, except per share amounts 2023 2022\nAssets:\nCash and cash equivalents $ 8,196 $ 12,945\nInvestments 3,259 2,778\nAccounts receivable, net 35,227 27,276\nInventories 18,025 19,090\nAssets held for sale — 908\nOther current assets 3,151 2,636\nTotal current assets 67,858 65,633\nLong-term investments 23,019 21,096\nProperty and equipment, net 13,183 12,873\nOperating lease right-of-use assets 17,252 17,872\nGoodwill 91,272 78,150\nIntangible assets, net 29,234 24,803\nSeparate accounts assets 3,250 3,228\nOther assets 4,660 4,620\nTotal assets $ 249,728 $ 228,275\nLiabilities:\nAccounts payable $ 14,897 $ 14,838\nPharmacy claims and discounts payable 22,874 19,423\nHealth care costs payable 12,049 10,142\nPolicyholders’ funds 1,326 1,500\nAccrued expenses 22,189 18,745\nOther insurance liabilities 1,141 1,089\nCurrent portion of operating lease liabilities 1,741 1,678\nShort-term debt 200 —\nCurrent portion of long-term debt 2,772 1,778\nLiabilities held for sale — 228\nTotal current liabilities 79,189 69,421\nLong-term operating lease liabilities 16,034 16,800\nLong-term debt 58,638 50,476\nDeferred income taxes 4,311 4,016\nSeparate accounts liabilities 3,250 3,228\nOther long-term insurance liabilities 5,459 5,835\nOther long-term liabilities 6,211 6,730\nTotal liabilities 173,092 156,506\nCommitments and contingencies (Note 18)\nShareholders’ equity:\nPreferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding — —\nCommon stock, par value $0.01: 3,200 shares authorized; 1,768 shares issued and 1,288 shares outstanding at\nDecember 31, 2023 and 1,758 shares issued and 1,300 shares outstanding at December 31, 2022 and capital\nsurplus 48,992 48,193\nTreasury stock, at cost: 480 and 458 shares at December 31, 2023 and 2022 (33,838) (31,858)\nRetained earnings 61,604 56,398\nAccumulated other comprehensive loss (297) (1,264)\nTotal CVS Health shareholders’ equity 76,461 71,469\nNoncontrolling interests 175 300\nTotal shareholders’ equity 76,636 71,769\nTotal liabilities and shareholders’ equity $ 249,728 $ 228,275"
] | CVS HEALTH Corp | CVS | 2,024 | 2024-02-07 | 64,803 | Healthcare | https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm | 148 | 0 |
What is the total operating revenue of Verizon Communications Inc. for the year ending Decmber 31st, 2023? | The total operating revenue for Verizon Communications for FY2023 was $133,974 million. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 149 | 0 |
What is the YoY growth of Verizon Communications Inc.'s total operating reveue between FY2022 and FY2023? | Verizon's total operating revenue between FY2022 and FY2023 declined by 2.09% | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 150 | 0 |
What is the operating revenue of Verizon Communications Inc. from Services for the FY2023? | The operating revenue for Verizon Communications from Services for FY2023 was $109,652 million. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 151 | 0 |
What is the operating revenue of Verizon Communications Inc. from Wireless equipments for the FY2022? | The operating revenue for Verizon Communications from wireless equipment for FY2022 was $27,210 million. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 152 | 0 |
What was Verizon Communications Inc's total cost of revenue for FY 2023? | Verizon Communications Inc's total cost of revenue for FY 2023 was $54,887 million | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 153 | 0 |
What was Verizon Communications Inc.'s Gross Margin for FY 2021? | Verizon Communications Inc's Gross Margin for FY 2021 was $77,312 million | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 154 | 0 |
How much were the Depreciation and amortization expenses for Verizon Communications Inc. in FY2023? | The Depreciation and ammortization expenses for Verizon in FY2023 were $17,624 million | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 155 | 0 |
How much were the Selling, general and administrative costs for Verizon Communications Inc. in FY2022? | Verizon Communications Inc's Selling, General and Administrative cost for FY 2022 was $30,136 million | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 156 | 0 |
How much was the goodwill impairment for Verizon Communications Inc. in FY2023? | The goodwill impairment for Verizon in FY2023 was $5,841 million | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 157 | 0 |
How much change did Verizon Communications Inc.'s cost of wireless equipment observe in percentage terms from FY2022 to FY2023? | Verizon's cost of wireless equipment fell by 12.16% to $26,787 million from FY2022 to FY2023 | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 158 | 0 |
What is the percentage increase/decrease in the total operating revenue from FY2021 to FY2022 for Verizon Communications Inc.? | The percentage increase in Verizon Communications Inc's total operating revenue from FY2021 TO FY2022 was 2.41%. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 159 | 0 |
What is Verizon Communications Inc.'s basic EPS for FY2023? | Verizon Communications Inc's basic EPS for FY2023 was $2.76. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 160 | 0 |
What is Verizon Communications Inc.'s diluted EPS for FY2021? | Verizon Communications Inc's diluted EPS for FY2021 was $5.32. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 161 | 0 |
What is the YoY growth between FY21 and FY23, on the basic EPS of Verizon Communications Inc.? | Verizon Communication Inc's basic EPS fell by 48.12% from FY2021 to FY2023. | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 162 | 0 |
What is the quick ratio of Verizon Communications Inc. for FY2023? | The quick ratio for Verizon Communication for FY2023 was 0.653 | [
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 163 | 0 |
By how much has the quick ratio increased/decreased in FY2023 from FY2022? | Verizon's quick ratio was 0.707 in FY2022. It has decreased by 7.64% in FY2023 | [
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 164 | 0 |
What was the current ratio of Verizon Communications Inc. for FY2023? | The current ratio for Verizon Communication for FY2023 was 0.692 | [
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 165 | 0 |
What was the Day Sales Outstanding for Verizon Communications Inc. in FY2023? | Verizon Communication's DSO for FY2023 comes out to be 70.06 days | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150",
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 166 | 0 |
Has the DSO increased / decreased from FY2022? If so, by how much? | The DSO for Verizon increased by 2.48 days from FY2022 | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150",
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 167 | 0 |
What was the Days Payables Outstanding for Verizon Communications Inc. in FY2023? | The Days Payables Outstanding ratio for Verizon in FY2023 was 155.96 days | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150",
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 168 | 0 |
What was the Days Inventory Outstanding for Verizon Communications Inc. in FY2023? | Verizon's Days Inventory Outstanding in FY2023 was 13.68 days | [
"Consolidated Statements of Income Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) Years Ended December 31, 2023 2022 2021 Operating Revenues Service revenues and other $ 109,652 $ 109,625 $ 110,449 Wireless equipment revenues 24,322 27,210 23,164 Total Operating Revenues 133,974 136,835 133,613 Operating Expenses Cost of services (exclusive of items shown below) 28,100 28,637 31,234 Cost of wireless equipment 26,787 30,496 25,067 Selling, general and administrative expense 32,745 30,136 28,658 Depreciation and amortization expense 17,624 17,099 16,206 Verizon Business Group goodwill impairment 5,841 — — Total Operating Expenses 111,097 106,368 101,165 Operating Income 22,877 30,467 32,448 Equity in earnings (losses) of unconsolidated businesses (53) 44 145 Other income (expense), net (313) 1,373 312 Interest expense (5,524) (3,613) (3,485) Income Before Provision For Income Taxes 16,987 28,271 29,420 Provision for income taxes (4,892) (6,523) (6,802) Net Income $ 12,095 $ 21,748 $ 22,618 Net income attributable to noncontrolling interests $ 481 $ 492 $ 553 Net income attributable to Verizon 11,614 21,256 22,065 Net Income $ 12,095 $ 21,748 $ 22,618 Basic Earnings Per Common Share Net income attributable to Verizon $ 2.76 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,211 4,202 4,148 Diluted Earnings Per Common Share Net income attributable to Verizon $ 2.75 $ 5.06 $ 5.32 Weighted-average shares outstanding (in millions) 4,215 4,204 4,150",
"Consolidated Balance Sheets Verizon Communications Inc. and Subsidiaries (dollars in millions, except per share amounts) At December 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 2,065 $ 2,605 Accounts receivable 26,102 25,332 Less Allowance for credit losses 1,017 826 Accounts receivable, net 25,085 24,506 Inventories 2,057 2,388 Prepaid expenses and other 7,607 8,358 Total current assets 36,814 37,857 Property, plant and equipment 320,108 307,689 Less Accumulated depreciation 211,798 200,255 Property, plant and equipment, net 108,310 107,434 Investments in unconsolidated businesses 953 1,071 Wireless licenses 155,667 149,796 Goodwill 22,843 28,671 Other intangible assets, net 11,057 11,461 Operating lease right-of-use assets 24,726 26,130 Other assets 19,885 17,260 Total assets $ 380,255 $ 379,680 Liabilities and Equity Current liabilities Debt maturing within one year $ 12,973 $ 9,963 Accounts payable and accrued liabilities 23,453 23,977 Current operating lease liabilities 4,266 4,134 Other current liabilities 12,531 12,097 Total current liabilities 53,223 50,171 Long-term debt 137,701 140,676 Employee benefit obligations 13,189 12,974 Deferred income taxes 45,781 43,441 Non-current operating lease liabilities 20,002 21,558 Other liabilities 16,560 18,397 Total long-term liabilities 233,233 237,046 Commitments and Contingencies (Note 16) Equity Series preferred stock ($0.10 par value; 250,000,000 shares authorized; none issued) — — Common stock ($0.10 par value; 6,250,000,000 shares authorized in each period; 4,291,433,646 shares issued in each period) 429 429 Additional paid in capital 13,631 13,420 Retained earnings 82,915 82,380 Accumulated other comprehensive loss (1,380) (1,865) Common stock in treasury, at cost (87,172,997 and 91,572,258 shares outstanding) (3,821) (4,013) Deferred compensation – employee stock ownership plans (ESOPs) and other 656 793 Noncontrolling interests 1,369 1,319 Total equity 93,799 92,463 Total liabilities and equity $ 380,255 $ 379,680"
] | VERIZON COMMUNICATIONS INC | VZ | 2,024 | 2024-02-09 | 732,712 | Communication Services | https://www.sec.gov/Archives/edgar/data/732712/000073271224000010/vz-20231231.htm | 169 | 0 |